Both in Biotechnology
Liminatus Pharma vs PharmaCyte Biotech
Over the past year LIMN returned −95.3% and PMCB returned −57.2%; their daily moves had a correlation of -0.05.
LIMN −95.3% PMCB −57.2%Growth of $1, one year, split-adjusted
| Metric | LIMN | PMCB |
|---|---|---|
| Price | $3.91 | $0.4190 |
| Market cap | $5.3M | $4.5M |
| Today | −8.43% | −0.21% |
| 1 month | −7.6% | −18.6% |
| 6 months | −55.8% | −37.6% |
| Year to date | −87.2% | −42.1% |
| 1 year | −94.6% | −56.8% |
| Revenue growth (YoY) | — | — |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | — | — |
| Net cash | — | $30.5M |
| Dividend yield | — | — |
| Volatility (60d) | 1,154.9% | 58.7% |
| Short % of float | 0.2% | 0.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).